THE VALSARTAN SAGA: SCIENCE, MYTHS AND REALTIES

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-RSC-008
• By: BALDACCHINO, Stephania (University of Malta, Pharmacy Department, Malta)
• Co-author(s): Stephania Baldacchino: Pharmacy Department, University of Malta, Msida, Malta
  Anthony Serracino-Inglott: Malta Medicines Authority , Malta Medicines Authority, San Gwann, Malta;Pharmacy Department, University of Malta, Msida, Malta
  Annalise Attard: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
  Caroline Muscat: Malta Medicines Authority, Malta Medicines Authority, San Gwann, Malta
  
• Abstract:

  Background

  Detection of N-nitrosodimethylamine (NDMA), a potential human carcinogen in the manufacture of the valsartan active pharmaceutical ingredient, led to the withdrawal of several contaminated valsartan medicinal products. 

  Methods

  Part I involved an in-depth analysis of the significance of the NDMA impurity in valsartan medicines through a

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login